- 2024,04,27
Securities code: 603811 Securities abbreviation: Cheng Yi Pharmaceutical Announcement number: 2024-002
Zhejiang Cheng Yi Pharmaceutical Co.,Ltd.
Announcement on Holding Subsidiaries Recognized as High tech Enterprises
The board of directors and all directors of our company guarantee that there are no false records, misleading statements, or significant omissions in the content of this announcement, and assume individual and joint liability for the authenticity, accuracy, and completeness of its content.
Recently, the Office of the Leading Group for the Recognition and Management of National High tech Enterprises issued a notice on the filing of the second batch of high-tech enterprises recognized and reported by Fujian Provincial Certification Institutions in 2023. Fujian Huakang Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), a subsidiary of Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), has been included in the list of the second batch of high-tech enterprises recognized and reported by Fujian Provincial Certification Institutions in 2023. The certificate number is GR202335003219, issued on December 28, 2023, and is valid for three years.
According to the relevant tax regulations of the state on high-tech enterprises, Huakang Pharmaceutical can enjoy the relevant preferential policies of the state on high-tech enterprises for three consecutive years (i.e. from 2023 to 2025) after passing the high-tech enterprise recognition, that is, pay enterprise income tax at a rate of 15%.
The first recognition of Huakang Pharmaceutical's high-tech enterprise is a full recognition of Huakang Pharmaceutical's technological strength and research and development level, which is conducive to reducing the enterprise's tax burden and will have a positive driving effect on the business development of Huakang Pharmaceutical.
This announcement is hereby made.
Board of Directors of Zhejiang Cheng Yi Pharmaceutical Co., Ltd
January 24, 2024